Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy

Panelists discuss how clinicians should interpret Clinical Dementia Rating-Sum of Boxes (CDR-SB) score changes by correlating numerical shifts with meaningful real-world outcomes, considering both the statistical significance and clinical meaningfulness of changes, recognizing that even modest improvements may represent significant functional preservation for patients, and contextualizing these changes within individual patient circumstances, disease trajectory, and impact on quality of life.

EP: 1.Strategies for Enhancing Early Diagnosis and Implementation of Disease-Modifying Therapies in Alzheimer Disease

EP: 2.Advancing Early Alzheimer Diagnosis: Best Practices for Timely Screening and Detection

EP: 3.Care Pathways for Nonspecialist Providers When Evaluating Patients With Potential Mild Cognitive Impairment

EP: 4.Empowering Nonspecialist Providers and Addressing Gaps in Dementia Care: How Tools and Biomarkers Can Help

EP: 5.Factors to Evaluate When Selecting a Combination of Screening Assessments and Tests for Detecting Alzheimer Disease

EP: 6.From Time Constraints to Reimbursement: Addressing Key Hurdles in Cognitive Screening for Alzheimer Disease

EP: 7.Expanding Access to Alzheimer Disease Care: Leveraging Referral Networks and Telemedicine for Patients in Underserved Areas

EP: 8.Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations

Now Viewing

EP: 9.Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy

EP: 10.Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations

EP: 11.Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease

EP: 12.Navigating the Risk-Benefit Conversation: Discussing Amyloid-Targeting Therapies With Patients and Caregivers

EP: 13.Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy

EP: 14.Strategies for Clinicians When Developing Protocols for Managing ARIA

EP: 15.Key Barriers in Managing Patients With Mild Cognitive Impairment Using Amyloid-Targeting Therapies

Video content above is prompted by the following:

• How should clinicians interpret changes in CDR-SB scores in terms of real-world functional and cognitive benefits for patients?

Related Videos

Related Content

Advertisement

April 24th 2025

Science at AACR Aims to Overcome Cancer Care Barriers

Mary Caffrey Brooke McCormick

A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for Cancer Research annual meeting runs April 25-30, with the key presentations coming Sunday through Tuesday.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 23rd 2025

Contributor: For Complex Cases, Continuity in Acute Care Is Necessary

Jubril Oyeyemi, MD

For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 22nd 2025

Overweight-to-Obese Trajectory in Adulthood May Raise Ovarian Cancer Risk

Brooke McCormick

Individuals who transition from overweight to obese during adulthood may face a higher ovarian cancer risk, highlighting the importance of tracking body fat changes.

April 18th 2025

5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas

Brooke McCormick

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

Related Content

Advertisement

April 24th 2025

Science at AACR Aims to Overcome Cancer Care Barriers

Mary Caffrey Brooke McCormick

A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for Cancer Research annual meeting runs April 25-30, with the key presentations coming Sunday through Tuesday.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 23rd 2025

Contributor: For Complex Cases, Continuity in Acute Care Is Necessary

Jubril Oyeyemi, MD

For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 22nd 2025

Overweight-to-Obese Trajectory in Adulthood May Raise Ovarian Cancer Risk

Brooke McCormick

Individuals who transition from overweight to obese during adulthood may face a higher ovarian cancer risk, highlighting the importance of tracking body fat changes.

April 18th 2025

5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas

Brooke McCormick

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.